{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Comparison between the Complete Remission Rate (CRR), percentage of patient in complete remission, before and after maintenance therapy","groups":[{"description":"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin.","id":"OG000","title":"One Arm"}],"populationDescription":"Due the early interruption of the trial, this end point was not evaluated.","reportingStatus":"POSTED","timeFrame":"The endpoint will be assessed at each restaging through study completion, up to 26 months.","title":"Role of Daratumumab Maintenance","type":"OTHER_PRE_SPECIFIED"}